预定位
化学
体内分布
体内
离体
药理学
单克隆抗体
药代动力学
放射免疫疗法
MUC1号
抗体
放射性配体
生物物理学
谷氨酸羧肽酶Ⅱ
去唾液酸糖蛋白受体
免疫毒素
清理
体外
融合蛋白
细胞生物学
作者
Samantha Delaney,Charlotte Lund Denholt,Jacob Madsen,Andreas Kjær,Matthias M. Herth,Umberto Maria Battisti
标识
DOI:10.1021/acs.bioconjchem.6c00444
摘要
In vivo pretargeting based on the inverse electron-demand Diels-Alder reaction between a trans-cyclooctene (TCO)-modified monoclonal antibody (mAb) and a radiolabeled tetrazine (Tz) is a highly effective approach for reducing radiation burden in nuclear imaging and therapy. However, the large size and slow pharmacokinetics of full-length immunoglobulins greatly hinder their bloodstream clearance. To circumvent this limitation of pretargeting, much effort has been put towards developing masking or clearing agents: molecules designed to be injected prior to the radioligand to rid the bloodstream of excess circulating TCO-mAbs via clearance organs. Yet even with the use of previously established clearing agents, high levels of TCO-mAb still remain in circulation. Moreover, some of these agents could lead to aggregate formation in the lungs or clogs in the bloodstream. Recently, a novel class of cell-surface protein degraders called lysosome-targeting chimeras (LYTACs) have been reported to simultaneously bind hepatocytic-expressed asialoglycoprotein receptor (ASGPR) and a harmful, disease-relevant protein, internalizing the latter for lysosomal degradation. Herein, we present a novel ASGPR-targeted tetrazine-bearing LYTAC TriGalNAc-Tz (LYTAC-Tz) as a clearing agent for pretargeting. First, the essential components of the pretargeted system were synthesized: LYTAC-Tz, a TCO-modified variant of the mAb CC49 (TCO-CC49), and an 111In-labeled DOTA-bearing Tz ([111In]In-DOTA-Tz). Then, LYTAC-Tz was evaluated in vivo for its efficacy as a clearing agent for pretargeting in a murine model of colorectal cancer. SPECT-CT images and ex vivo biodistribution data revealed that LYTAC-Tz resulted in lower blood activity levels than control cohorts along with higher tumor-to-blood ratios. Healthy organs boasted low activity levels (excluding the kidneys, which showed uptake due to their rapid excretion of excess radioligand). Ultimately, this work illustrates that LYTAC-Tzs are effective clearing agents and could be beneficial for reducing radiotoxicity in pretargeted systems.
科研通智能强力驱动
Strongly Powered by AbleSci AI